You are here

Article info

Article menu
Download PDFPDF
Viewpoint
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example

Authors

  • Robert B M Landewé Amsterdam Rheumatology & immunology Center, Academic Medical Center/University of Amsterdam, The Netherlands Department of Rheumatology, Atrium Medical Center Heerlen, The Netherlands PubMed articlesGoogle scholar articles
  • Josef S Smolen Division of Rheumatology, Department of Medicine Three, Medical University Vienna & Second Department of Medicine, Hietzing Hospital, Vienna, Austria PubMed articlesGoogle scholar articles
  • Michael E Weinblatt Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital Harvard Medical School, Boston, USA PubMed articlesGoogle scholar articles
  • Paul Emery Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK PubMed articlesGoogle scholar articles
  • Maxime Dougados Rheumatology Department, Paris Descartes University, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, Fance PubMed articlesGoogle scholar articles
  • Roy Fleischmann Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA PubMed articlesGoogle scholar articles
  • Daniel Aletaha Division of Rheumatology, Department of Medicine Three, Medical University Vienna, Austria PubMed articlesGoogle scholar articles
  • Arthur Kavanaugh Rheumatology, Allergy, Immunology Division, University of California, San Diego, USA PubMed articlesGoogle scholar articles
  • Désirée van der Heijde Department of rheumatology, Leiden University Medical Center, Leiden, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Robert B M Landewé, Department of Rheumatology & Clinical Immunology, Academic Medical Center, Meibergdreef 9, Amsterdam 1100 DD, The Netherlands; Landewe{at}rlandewe.nl
View Full Text

Citation

Landewé RBM, Smolen JS, Weinblatt ME, et al
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
Annals of the Rheumatic Diseases 2014;73:1755-1760.

Publication history

  • Received April 28, 2014
  • Revised June 24, 2014
  • Accepted July 20, 2014
  • First published August 11, 2014.
Online issue publication 
April 11, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions